CT Healthcare Trust net asset value falls 3% but beats benchmark
(Alliance News) - CT Healthcare Trust PLC on Monday reported a decline in interim net asset value, although it outperformed its benchmark over the period.
The London-based investment trust reported a net asset value per share of 142.23 pence as of May 31, down 3.0% from 146.58 pence at November 30.
NAV total return decreased 1.1% in the six months to May 31, outperforming its benchmark, the MSCI World Healthcare Index, which declined 5.1%.
The company paid a dividend of 2.7 pence per share on May 29, equivalent to 3.5% of CT Healthcare's NAV at the end of the previous financial year, in line with company policy. A further dividend of 2.565 pence per share will be paid on September 18 to shareholders on the register on 28 August 2026, with an ex-dividend date of August 27.
Looking ahead, the fund manager said the healthcare sector has performed strongly, but believes the broad rally is unlikely to continue through the second half of 2026.
Nevertheless, the manager remains moderately positive on the sector, with stock selection expected to be key. Ongoing questions around drug pricing and trade policy are making investors cautious about paying higher valuations for larger pharmaceutical companies.
CT Healthcare Trust shares closed up 1.0% at 140.80 pence in London on Monday.
By Camilla Borri, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
12 Best Blue-Chip Stocks to Buy for the Long Term
The 10 Best Dividend Stocks
United States